Formulation and biopharmaceutical evaluation of risperidone-loaded chitosan nanoparticles for intranasal delivery

References

• Higashi K, Medic G, Littlewood KJ, et al. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Ther Adv Psychopharmacol. 2013;3:200–218.
   PubMedGoogle Scholar
• Mauri MC, Paletta S, Maffini M, et al. Clinical pharmacology of atypical antipsychotics: an update. EXCLI J. 2014;13:1163–1191.
   PubMed Web of Science ®Google Scholar
• Gu F, Ma W, Meng G, et al. Preparation and in vivo evaluation of a gel-based nasal delivery system for risperidone. Acta Pharm. 2016;66:555–562.
   PubMed Web of Science ®Google Scholar
• Grant S, Fitton A. Risperidone. A review of its pharmacology and therapeutic potential in the treatment of schizophrenia. Drugs. 1994;48:253–273.
   PubMed Web of Science ®Google Scholar
• Miyamoto S, Duncan GE, Marx CE, et al. Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Mol Psychiatry. 2005;10:79–104.
   PubMed Web of Science ®Google Scholar
• Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry. 1994;151:825–835.
   PubMed Web of Science ®Google Scholar
• Alzubaidi AF, El-Helw AM, Ahmed TA, et al. The use of experimental design in the optimization of risperidone biodegradable nanoparticles: in vitro and in vivo study. Artif Cells Nanomed Biotechnol. 2017;45:313–320.
   PubMed Web of Science ®Google Scholar
• Aggarwal G, Dhawan S, Hari Kumar SL. Formulation, in vitro and in vivo evaluation of transdermal patches containing risperidone. Drug Dev Ind Pharm. 2013;39:39–50.
   PubMed Web of Science ®Google Scholar
• Thomson SR, Chogtu B, Bhattacharjee D, et al. Extrapyramidal symptoms probably related to risperidone treatment: a case series. Ann Neurosci. 2017;24:155–163.
   PubMed Web of Science ®Google Scholar
• Muthu MS, Rawat MK, Mishra A, et al. PLGA nanoparticle formulations of risperidone: preparation and neuropharmacological evaluation. Nanomedicine. 2009;5:323–333.
   PubMed Web of Science ®Google Scholar
• Aljaeid BM, El-Say KM, Hosny KM. Chitosan-TPP nanoparticles stabilized by poloxamer for controlling the release and enhancing the bioavailability of doxazosin mesylate: in vitro, and in vivo evaluation. Drug Dev Ind Pharm. 2019;18:1–10.
   Google Scholar
• Badshah A, Subhan F, Rauf K, et al. Development of controlled-release matrix tablet of risperidone: influence of Methocel®- and Ethocel®-based novel polymeric blend on in vitro drug release and bioavailability. AAPS PharmSciTech. 2011;12:525–533.
   PubMed Web of Science ®Google Scholar
• Fazil M, Shadab M, Haque S, et al. Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting. Eur J Pharm Sci. 2012;47:6–15.
   PubMed Web of Science ®Google Scholar
• Zhang J, Xia W, Liu P, et al. Chitosan modification and pharmaceutical/biomedical applications. Mar Drugs. 2010;8:1962–1987.
   PubMed Web of Science ®Google Scholar
• Mittal D, Ali A, Shadab M, et al. Insights into direct nose to brain delivery: current status and future perspective. Drug Deliv. 2014;21:75–86.
   PubMed Web of Science ®Google Scholar
• Cheung RCF, Ng TB, Wong JH, et al. Chitosan: an update on potential biomedical and pharmaceutical applications. Mar Drugs. 2015;13:5156–5186.
   PubMed Web of Science ®Google Scholar
• Fan W, Yan W, Xu Z, et al. Formation mechanism of monodisperse, low molecular weight chitosan nanoparticles by ionic gelation technique. Colloids Surf B Biointerfaces. 2012;90:21–27.
   PubMed Web of Science ®Google Scholar
• Sobhani Z, Mohammadi Samani S, Montaseri H, et al. Nanoparticles of chitosan loaded ciprofloxacin: fabrication and antimicrobial activity. Adv Pharm Bull. 2017;7:427–432.
   PubMed Web of Science ®Google Scholar
• Mittal D, Md S, Hasan Q, et al. Brain targeted nanoparticulate drug delivery system of rasagiline via intranasal route. Drug Deliv. 2016;23:130–139.
   PubMed Web of Science ®Google Scholar
• Prasanna Raju Y, Hyndavi N, Harini Chowdary V, et al. In vitro assessment of non-irritant microemulsified voriconazole hydrogel system. Artif Cells Nanomed Biotechnol. 2017;45:1539–1547.
   PubMed Web of Science ®Google Scholar
• Patel BK, Parikh RH, Aboti PS. Development of oral sustained release rifampicin loaded chitosan nanoparticles by design of experiment. J Drug Deliv. 2013;2013:1.
   Google Scholar
• Nanda Kishore R, Yalavarthi PR, Vadlamudi HC, et al. Solid self microemulsification of atorvastatin using hydrophilic carriers: a design. Drug Dev Ind Pharm. 2015;41:1213–1222.
   PubMed Web of Science ®Google Scholar
• Tong GF, Qin N, Sun LW. Development and evaluation of desvenlafaxine loaded PLGA-chitosan nanoparticles for brain delivery. Saudi Pharm J. 2017;25:844–885.
   PubMed Web of Science ®Google Scholar
• Yin Y, Chen D, Qiao M, et al. Preparation and evaluation of lectin-conjugated PLGA nanoparticles for oral delivery of thymopentin. J Control Rel. 2006;116:337–345.
   PubMed Web of Science ®Google Scholar
• Yasir M, Sara U. Solid lipid nanoparticles for nose to brain delivery of haloperidol: in vitro drug release and pharmacokinetics evaluation. Acta Pharm Sinica B. 2014;4:454–463.
   PubMed Web of Science ®Google Scholar
• Dedania ZR, Dedania RR, Sheth NR, et al. Stability Indicating HPLC determination of risperidone in bulk drug and pharmaceutical formulations. Int J Anal Chem. 2011;2011:1.
   Google Scholar
• Rukmangathen R, Yallamalli IM, Yalavarthi PR. Biopharmaceutical potential of selegiline loaded chitosan nanoparticles in the management of Parkinson’s disease. Curr Drug Discov Technol. 2018. DOI: 10.2174/1570163815666180418144019
   PubMedGoogle Scholar
• McNamara R, Logue A, Stanford K, et al. Dose-response analysis of locomotor activity and stereotypy in dopamine D3 receptor mutant mice following acute amphetamine. Synapse. 2006;60:399–405.
   PubMed Web of Science ®Google Scholar
• Conti LH, Segal DS, Kuczenski R. Maintenance of amphetamine-induced stereotypy and locomotion requires ongoing dopamine receptor activation. Psychopharmacology. 1997;130:183–188.
   PubMed Web of Science ®Google Scholar
• Harini Chowdary V, Yalavarthi PR, Nagaswaram T, et al. In-vitro and pharmacodynamic characterization of solidified self microemulsified system of quetiapine fumarate. J Pharm Investig. 2019;49:161–172.
   Google Scholar
• Guan HJ, Dai J, Zhu XZ. Atypical antipsychotic effects of quetiapine fumarate in animal models. Acta Pharmacol Sin. 2000;21:205–210.
   PubMed Web of Science ®Google Scholar
• Wilson B, Samanta MK, Santhi K, et al. Chitosan nanoparticles as a new delivery system for anti-Alzheimer drug tacrine. Nanomedicine. 2010;6:144–152.
   PubMed Web of Science ®Google Scholar
• Shalaby KS, Soliman ME, Casettari L, et al. Determination of factors controlling the particle size and entrapment efficiency of noscapine in PEG/PLA nanoparticles using artificial neural networks. Int J Nanomedicine. 2014;9:4953–4964.
   PubMed Web of Science ®Google Scholar
• Peltonen L, Hirvonen J. Pharmaceutical nanocrystals by nanomilling: critical process parameters, particle fracturing and stabilization methods. J Pharm Pharmacol. 2010;62:1569–1579.
   PubMed Web of Science ®Google Scholar
• Ravikumara NR, Madhusudhan B. Chitosan nanoparticles for tamoxifen delivery and cytotoxicity to MCF-7 and Vero cells. Pure Appl Chem. 2011;83:2027–2040.
   Web of Science ®Google Scholar
• Miyamoto M, Natsume H, Iwata S, et al. Improved nasal absorption of drugs using poly-l-arginine: effects of concentration and molecular weight of poly-l-arginine on the nasal absorption of fluorescein isothiocyanate-dextran in rats. Eur J Pharm Biopharm. 2001;52:21–30.
   PubMed Web of Science ®Google Scholar
• Neves AR, Queiroz JF, Reis S. Brain-targeted delivery of resveratrol using solid lipid nanoparticles functionalized with apolipoprotein E. J Nanobiotechnol. 2016;14:27.
   PubMed Web of Science ®Google Scholar
• Kreuter J. Influence of the surface properties on nanoparticle-mediated transport of drugs to the brain. J Nanosci Nanotechnol. 2004;4:484–488.
   PubMed Web of Science ®Google Scholar
• Kreuter J. Nanoparticulate systems for brain delivery of drugs. Adv Drug Deliv Rev. 2012;64:213–222.
   Web of Science ®Google Scholar
• Kirgaval RS, Revanakar S, Srirangapattna C. Prevalence of extrapyramidal side effects in patients on antipsychotics drugs at a tertiary care center 5. J Psychiatry. 2017;20:419–424.
   Google Scholar
• Singh R, Lillard JW. Nanoparticle-based targeted drug delivery. Exp Mol Pathol. 2009;86:215–223.
   PubMed Web of Science ®Google Scholar